FONAR Corp. (FONR) Stock Price Forecast & Company Overview
This article provides a brief analysis and stock rating for FONAR Corp. (FONR) including an updated stock price target. Additional data on the company’s earnings yield, price/earnings ratio, return on invested capital and YTD performance are discussed as well.
FONAR Corp. Fundamentals
Stock Price Target: $20.73
In the section below, we discuss the earnings yield, P/E, return on invested capital and YTD performance for FONAR in comparison to the Healthcare Products industry and the S&P 500.
FONAR is a Micro Cap company with a current Market Cap of $102.9M.
| FONAR Corp. | Healthcare Products | S&P 500 | T-Bill (10Y) |
|---|---|---|---|
| 30.76% | 3.05% | 2.94% | 1.51% |
The current earnings yield for FONAR is 30.76%, in comparison to 2.94% for the S&P 500 and 1.51% for the 10-year treasury bond. The median earnings yield for the Healthcare Products industry is 3.05%.
| FONAR Corp. | Healthcare Products | S&P 500 |
|---|---|---|
| 10.74 | 52.73 | 34.01 |
FONAR is currently trading at a P/E of 10.74. The P/E for the Healthcare Products industry is 52.73 and the P/E for the S&P 500 is 34.01.
| FONAR Corp. | Healthcare Products | S&P 500 |
|---|---|---|
| 1.16 | 6.94 | 3.09 |
FONAR is currently trading at a P/S of 1.16. The P/S for the Healthcare Products industry is 6.94 and the P/S for the S&P 500 is 3.09.
| FONAR Corp. | Healthcare Products | S&P 500 |
|---|---|---|
| 0.74 | 5.77 | 4.58 |
FONAR is currently trading at a P/B of 0.74. The P/B for the Healthcare Products industry is 5.77 and the P/B for the S&P 500 is 4.58.
Return on Invested Capital (ROIC)
| FONAR Corp. | Healthcare Products | S&P 500 |
|---|---|---|
| 6.23% | 11.61% | 8.6% |
FONAR ROIC is currently 6.23% in comparison to 11.61% for the Healthcare Products industry and 8.6% for the S&P 500.
| FONAR Corp. | Healthcare Products | S&P 500 |
|---|---|---|
| -9.74% | 15.54% | 17.14% |
The YTD performance for FONAR is -9.74%. The Healthcare Products industry has a YTD performance of 15.54% in comparison to the YTD S&P 500 performance of 17.14%.
Recent Financial Results
- Total Revenues increased by 5% to $89.9M for the current fiscal year versus the previous fiscal year
- Income from Operations increased to $17.1M
- Net Income of $13.7M for the fiscal year
- Diluted Net Income per share of $1.45
- Book Value per share increased by 6% to $20.41 for the fiscal year
- Cash and short term investments increased 21% to $44.5 million
- Total Assets of $189.5M
- Total Liabilities of $54.1M
- Ratio of Total Assets / Total Liabilities increased 5% to 3.5 YoY
- Total Current Assets of $108.6 million as compared to $95.9 million in the previous fiscal year
- Working Capital increased 15% to $88.5M YoY
Stock Price Target: $20.73
Company Overview
FONAR Corporation focuses on research and development for magnetic resonance imaging (MRI) scanners that are used to detect and diagnose of human diseases in the US. The company operates through two segments: Medical Equipment and Physician Management and Diagnostic services. It’s flagship product is the Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting or lying down.
The company owns and operates four diagnostic imaging facilities in Florida and manages 35 MRI scanning facilities, including 22 facilities located in New York. Fonar markets its scanners to private diagnostic imaging centers and hospitals.
The company was founded in 1978 and is based in Melville, New York. The current CEO is Timothy Damadian.
We keep you found this valuation helpful. Be sure to add FONR stock to your Watch List and if you haven’t done so already, check in on the performance of our Current Portfolio. Keep it simple and always do your due diligence.
This material is provided for informational purposes only and is not financial advice. The information contained herein should not solely be used for the formation of an investment decision, whether you are a long term or short term investor.